First approval for rivastigmin in Switzerland
Post on 13-Dec-2016
22 MARKET NEWS First approval for rivastigmin in Switzerland
IKS, the regulatory authority in Switzerland, has approved rivastigmin ['Exelon'; Novartis] for the treatment of mild-to-moderately severe Alzheimer's disease. The approval of rivastigmin was made via the Swiss regulatory authority's fast-track approvals procedure for treatments of life-threatening diseases.
Twice-daily administration Novartis claim that rivastigmin is superior to other
acetylcholinesterase inhibitors, as it confers benefit in patients' global functioning, cognition and activities of daily living. The drug is administered twice daily.
Rivastigmin is only the third drug to be approved for the treatment of patients with Alzheimer's disease, reports Scrip. EC approval for Novartis's Exelon. Scrip '2:157: 18, 12 Aug 1997
Inpharmae 23 Aug 1997 No, 1101 1173-8324197/1101-000221$01.00 Adl.lnternatlonal Llmitecl19117, All rlghU r_rvecI